Positron emission tomography of striatal serotonin transporters in Parkinson disease

被引:116
作者
Kerenyi, L
Ricaurte, GA
Schretlen, DJ
McCann, U
Varga, J
Mathews, WB
Ravert, HT
Dannals, RF
Hilton, J
Wong, DF
Szabo, Z
机构
[1] Med Sch Debrecen, Dept Neurol, Debrecen, Hungary
[2] Univ Debrecen, Dept Nucl Med, H-4012 Debrecen, Hungary
[3] Johns Hopkins Med Inst, Dept Radiol, Baltimore, MD 21287 USA
[4] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Div Nucl Med, Baltimore, MD USA
关键词
D O I
10.1001/archneur.60.9.1223
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Little is known about serotonin neurons in Parkinson disease (PD). Objective: To study the serotonin system in PD with positron emission tomography, using the serotonin transporter radioligand [C-11](+)McN5652. Design and Patients: We measured the density of the serotonin transporter and the density of [C-11]WIN35 428-labeled dopamine transporters in the striatum of 13 adults with PD and 13 age- and sex-matched controls. To assess the effects of possible differences in blood flow or brain atrophy, we also measured regional cerebral blood flow and the size of the regions of interest for the caudate nucleus and putamen. Results: Patients with PD showed reductions in the specific distribution volumes of [C-11] (+)McN5652 in the caudate (P<.01) and putamen (P<.01), along with the expected reductions in striatal [C-11]WIN35428 binding (P<.01). There were no reductions in regional cerebral blood flow or the sizes of the regions of interest, mitigating against potential confounding effects of blood flow, brain atrophy, or partial volume effects. Reductions in serotonin transporter binding correlated with ratings of disease staging. Conclusions: These results suggest that the density of serotonin transporters, like that of dopamine transporters, is reduced in the striatum of patients with PD and that these changes are related to disease stage.
引用
收藏
页码:1223 / 1229
页数:7
相关论文
共 46 条
[1]  
Bergstrom K A, 1994, J Nucl Biol Med, V38, P128
[2]  
BODDIE HG, 1989, J NEUROL NEUROSUR PS, V52, P77
[3]   Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism [J].
Booij, J ;
Tissingh, G ;
Winogrodzka, A ;
van Royen, EA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (02) :171-182
[4]   Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease [J].
Brooks, DJ .
JOURNAL OF NEUROLOGY, 2000, 247 (Suppl 2) :11-18
[5]   SPECT IMAGING OF DOPAMINE AND SEROTONIN TRANSPORTERS WITH [I-123] BETA-CIT - BINDING-KINETICS IN THE HUMAN BRAIN [J].
BRUCKE, T ;
KORNHUBER, J ;
ANGELBERGER, P ;
ASENBAUM, S ;
FRASSINE, H ;
PODREKA, I .
JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1993, 94 (02) :137-146
[6]   SEROTONINERGIC TERMINAL TRANSPORTERS ARE DIFFERENTIALLY AFFECTED IN PARKINSONS-DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY - AN AUTORADIOGRAPHIC STUDY WITH [H-3] CITALOPRAM [J].
CHINAGLIA, G ;
LANDWEHRMEYER, B ;
PROBST, A ;
PALACIOS, JM .
NEUROSCIENCE, 1993, 54 (03) :691-699
[7]  
Fahn S., 1987, RECENT DEV PARKINSON, P153
[8]  
First S., 1995, BIOMETRICS RES DEP
[9]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[10]   Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging [J].
Frey, KA ;
Koeppe, RA ;
Kilbourn, MR ;
VanderBorght, TM ;
Albin, RL ;
Gilman, S ;
Kuhl, DE .
ANNALS OF NEUROLOGY, 1996, 40 (06) :873-884